Free Newsletter
Gates earmarks $100M for microbicide R&D
The Bill & Melinda Gates Foundation has put up $100 million to further advance promising microbicidal gels that can significantly reduce the spread of HIV. The money was committed after the Maryland-based International Partnership for Microbicides, or IPM, reported positive results for a clinical trial involving a new gel.
There is no effective microbicide in use, but the IPM is convinced that a new product could save millions of lives. A gel would be particularly effective in developing countries where men are often reluctant to use a condom. And in January researchers for the NIH announced that the gel PRO2000 was 30 percent more effective than other products in preventing the spread of the virus in a mid-stage trial.
"IPM will bring pioneering HIV prevention technologies into 10 new clinical studies this year," said the IPM in a statement, including long-acting vaginal gels and vaginal rings that could provide sustained protection for up to a month."
- check out the report from the AFP
Related Articles:
Indevus HIV gel misses Phase III endpoint
Gates gives $168M for research into malaria vax
Has the Gates Foundation created a malaria 'cartel'?
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: